A pharmacokinetic study with the high-dose anticancer agent menadione in rabbits

Oliver Yoa Pu Hu, Chih Yuan Wu, Win Kai Chan, Felicia Y.H. Wu, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The aim of this investigation was to assess the pharmacokinetic properties of high-dose menadione (VK3), as an anticancer agent, in plasma and red blood cells (RBCs) in rabbits. An extremely high dose of 75 mg menadiol sodium diphosphate (Synkayvite) was intravenously injected. HPLC analysis was applied to measure the major metabolite, menadione, VK3. The kinetic properties of VK3 in both plasma and red blood cells showed a short elimination half-life, high clearance, and large volume of distribution in plasma and RBCs. The mean elimination t( 1/4 ) values of menadione in plasma and in RBCs were 27.17 ± 10.49 min and 35.22 ± 11.82 min, respectively. The plasma clearance (CL/F) of VK3 was 0.822 ± 0.254 L min-1. The systemic clearance in RBCs was 0.407 ± 0.152 L min-1. The apparent volume of distribution (V(d)/F) in plasma was 30.833 ± 12.835 L and that in RBCs 20.488 ± 9.401 L. The plasma AUC was 32.453 ± 9.785 μg min mL-1 and that of RBCs 67.219 ± 24.449 μg min mL-1. Menadiol was rapidly biotransformed to menadione in blood. The formation rate constant (k(f)) of menadione in plasma was 0.589 ± 0.246 min-1, and that of RBCs 1.520 ± 1.345 min-1. Through this study the estimated menadione dosage needed to maintain a plasma level of 1 μg mL-1 for anticancer purposes was 19.7 mg kg-1 every hour.

Original languageEnglish
Pages (from-to)493-499
Number of pages7
JournalBiopharmaceutics and Drug Disposition
Volume17
Issue number6
DOIs
Publication statusPublished - Aug 1 1996
Externally publishedYes

Fingerprint

Vitamin K 3
Antineoplastic Agents
Pharmacokinetics
Rabbits
Erythrocytes
Area Under Curve
Half-Life
High Pressure Liquid Chromatography

Keywords

  • menadiol sodium diphosphate (synkayvite)
  • menadione
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

A pharmacokinetic study with the high-dose anticancer agent menadione in rabbits. / Hu, Oliver Yoa Pu; Wu, Chih Yuan; Chan, Win Kai; Wu, Felicia Y.H.; Whang-Peng, Jacqueline.

In: Biopharmaceutics and Drug Disposition, Vol. 17, No. 6, 01.08.1996, p. 493-499.

Research output: Contribution to journalArticle

Hu, Oliver Yoa Pu ; Wu, Chih Yuan ; Chan, Win Kai ; Wu, Felicia Y.H. ; Whang-Peng, Jacqueline. / A pharmacokinetic study with the high-dose anticancer agent menadione in rabbits. In: Biopharmaceutics and Drug Disposition. 1996 ; Vol. 17, No. 6. pp. 493-499.
@article{11e1421ac280452fb0b08366468f94f5,
title = "A pharmacokinetic study with the high-dose anticancer agent menadione in rabbits",
abstract = "The aim of this investigation was to assess the pharmacokinetic properties of high-dose menadione (VK3), as an anticancer agent, in plasma and red blood cells (RBCs) in rabbits. An extremely high dose of 75 mg menadiol sodium diphosphate (Synkayvite) was intravenously injected. HPLC analysis was applied to measure the major metabolite, menadione, VK3. The kinetic properties of VK3 in both plasma and red blood cells showed a short elimination half-life, high clearance, and large volume of distribution in plasma and RBCs. The mean elimination t( 1/4 ) values of menadione in plasma and in RBCs were 27.17 ± 10.49 min and 35.22 ± 11.82 min, respectively. The plasma clearance (CL/F) of VK3 was 0.822 ± 0.254 L min-1. The systemic clearance in RBCs was 0.407 ± 0.152 L min-1. The apparent volume of distribution (V(d)/F) in plasma was 30.833 ± 12.835 L and that in RBCs 20.488 ± 9.401 L. The plasma AUC was 32.453 ± 9.785 μg min mL-1 and that of RBCs 67.219 ± 24.449 μg min mL-1. Menadiol was rapidly biotransformed to menadione in blood. The formation rate constant (k(f)) of menadione in plasma was 0.589 ± 0.246 min-1, and that of RBCs 1.520 ± 1.345 min-1. Through this study the estimated menadione dosage needed to maintain a plasma level of 1 μg mL-1 for anticancer purposes was 19.7 mg kg-1 every hour.",
keywords = "menadiol sodium diphosphate (synkayvite), menadione, pharmacokinetics",
author = "Hu, {Oliver Yoa Pu} and Wu, {Chih Yuan} and Chan, {Win Kai} and Wu, {Felicia Y.H.} and Jacqueline Whang-Peng",
year = "1996",
month = "8",
day = "1",
doi = "10.1002/(SICI)1099-081X(199608)17:6<493::AID-BDD972>3.0.CO;2-6",
language = "English",
volume = "17",
pages = "493--499",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - A pharmacokinetic study with the high-dose anticancer agent menadione in rabbits

AU - Hu, Oliver Yoa Pu

AU - Wu, Chih Yuan

AU - Chan, Win Kai

AU - Wu, Felicia Y.H.

AU - Whang-Peng, Jacqueline

PY - 1996/8/1

Y1 - 1996/8/1

N2 - The aim of this investigation was to assess the pharmacokinetic properties of high-dose menadione (VK3), as an anticancer agent, in plasma and red blood cells (RBCs) in rabbits. An extremely high dose of 75 mg menadiol sodium diphosphate (Synkayvite) was intravenously injected. HPLC analysis was applied to measure the major metabolite, menadione, VK3. The kinetic properties of VK3 in both plasma and red blood cells showed a short elimination half-life, high clearance, and large volume of distribution in plasma and RBCs. The mean elimination t( 1/4 ) values of menadione in plasma and in RBCs were 27.17 ± 10.49 min and 35.22 ± 11.82 min, respectively. The plasma clearance (CL/F) of VK3 was 0.822 ± 0.254 L min-1. The systemic clearance in RBCs was 0.407 ± 0.152 L min-1. The apparent volume of distribution (V(d)/F) in plasma was 30.833 ± 12.835 L and that in RBCs 20.488 ± 9.401 L. The plasma AUC was 32.453 ± 9.785 μg min mL-1 and that of RBCs 67.219 ± 24.449 μg min mL-1. Menadiol was rapidly biotransformed to menadione in blood. The formation rate constant (k(f)) of menadione in plasma was 0.589 ± 0.246 min-1, and that of RBCs 1.520 ± 1.345 min-1. Through this study the estimated menadione dosage needed to maintain a plasma level of 1 μg mL-1 for anticancer purposes was 19.7 mg kg-1 every hour.

AB - The aim of this investigation was to assess the pharmacokinetic properties of high-dose menadione (VK3), as an anticancer agent, in plasma and red blood cells (RBCs) in rabbits. An extremely high dose of 75 mg menadiol sodium diphosphate (Synkayvite) was intravenously injected. HPLC analysis was applied to measure the major metabolite, menadione, VK3. The kinetic properties of VK3 in both plasma and red blood cells showed a short elimination half-life, high clearance, and large volume of distribution in plasma and RBCs. The mean elimination t( 1/4 ) values of menadione in plasma and in RBCs were 27.17 ± 10.49 min and 35.22 ± 11.82 min, respectively. The plasma clearance (CL/F) of VK3 was 0.822 ± 0.254 L min-1. The systemic clearance in RBCs was 0.407 ± 0.152 L min-1. The apparent volume of distribution (V(d)/F) in plasma was 30.833 ± 12.835 L and that in RBCs 20.488 ± 9.401 L. The plasma AUC was 32.453 ± 9.785 μg min mL-1 and that of RBCs 67.219 ± 24.449 μg min mL-1. Menadiol was rapidly biotransformed to menadione in blood. The formation rate constant (k(f)) of menadione in plasma was 0.589 ± 0.246 min-1, and that of RBCs 1.520 ± 1.345 min-1. Through this study the estimated menadione dosage needed to maintain a plasma level of 1 μg mL-1 for anticancer purposes was 19.7 mg kg-1 every hour.

KW - menadiol sodium diphosphate (synkayvite)

KW - menadione

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0029795201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029795201&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1099-081X(199608)17:6<493::AID-BDD972>3.0.CO;2-6

DO - 10.1002/(SICI)1099-081X(199608)17:6<493::AID-BDD972>3.0.CO;2-6

M3 - Article

C2 - 8866040

AN - SCOPUS:0029795201

VL - 17

SP - 493

EP - 499

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 6

ER -